COVID-19 vaccine over 90 per cent effective: Pfizer
Pfizer and BioNTech said they have so far found no serious safety concerns and expect to seek US authorisation this month for…
Sign in
Sign in
Recover your password.
A password will be e-mailed to you.
Browsing Tag
Pfizer
IBRANCE (palbociclib) fails trial for early breast cancer treatment
No unexpected safety signals were observed and it did not meet improved invasive disease-free survival in women with HR+, HER2-…
Drug makers, BMGF pledge to strive for global access to COVID-19 diagnostics, therapeutics and…
They assured that they will work towards developing innovations to fight the COVID-19 pandemic, ensuring their timely availability…
Pfizer and CStone to collaborate for oncology therapies in China
CStone to receive up to $280 million in milestone payments for sugemalimab, and additional royalties
Pfizer get USFDA nod for XELJANZ (tofacitinib) to treat active polyarticular course juvenile…
Two formulations were approved, a tablet and an oral solution, and are dosed based upon weight
Vivet, Pfizer sign manufacturing pact for investigational gene therapy to treat Wilson disease
Terms of the agreement were not disclosed
BioNTech to buy site from Novartis to boost COVID-19 vaccine production
The financial details of the transaction have not been revealed but the facility in Germany’s Marburg will be converted to be…
Top 20 global pharma companies by MCap saw 10.2 per cent rise in MCap in Q2 2020: GlobalData
Johnson & Johnson maintained its top position with MCap growth of 7.2 per cent on a QoQ basis
Pfizer and BioNTech submit proposal to US FDA to expand COVID-19 vaccine trial
The companies expect that a conclusive readout on efficacy is likely by the end of October
Pfizer and BioNTech to potentially supply EU with 200 mn doses of COVID-19 vaccine candidate
The proposed agreement also has an option to purchase additional 100 million doses, with deliveries starting by the end of 2020,…